First startup to receive funding from Eli Lilly and Andreessen Horowitz techbio fund by end of 2025?
Startup A • 25%
Startup B • 25%
Startup C • 25%
Other • 25%
Official announcements from Eli Lilly or Andreessen Horowitz, or credible news outlets reporting on the funding.
Eli Lilly Partners with Andreessen Horowitz to Launch $500 Million Techbio Fund
Jan 10, 2025, 02:30 PM
Eli Lilly has announced a partnership with venture capital firm Andreessen Horowitz to establish a new fund aimed at supporting innovative startups at the intersection of life sciences and software/AI. The fund will be backed by $500 million from Eli Lilly, marking an unprecedented move for the pharmaceutical giant. This collaboration reflects Eli Lilly's ongoing commitment to the strategic venture model, which it has been developing for over a decade. The partnership is expected to focus on emerging areas of interest within the techbio sector, potentially influencing future trends in pharmaceutical and venture capital collaborations. Experts note that while venture capital funding is abundant, the real challenge lies in securing experienced management teams capable of navigating the complexities of research and development in the biopharma space.
View original story
Google • 25%
Amazon • 25%
Other • 25%
Microsoft • 25%
Company A • 25%
Company B • 25%
Company C • 25%
Other • 25%
Other • 25%
Johnson & Johnson • 25%
Eli Lilly • 25%
GSK • 25%
Other • 25%
Pfizer • 25%
GSK • 25%
Eli Lilly • 25%
Johnson & Johnson • 25%
Pfizer • 25%
Roche • 25%
Other • 25%
Novartis • 25%
Pfizer • 25%
Roche • 25%
Other • 25%
Other • 25%
Illumina • 25%
Truveta • 25%
Regeneron • 25%
Moderna • 25%
Other • 25%
BioNTech • 25%
Pfizer • 25%
$50 million to $100 million • 25%
More than $200 million • 25%
$100 million to $200 million • 25%
Less than $50 million • 25%
$100 million to $200 million • 25%
Less than $100 million • 25%
More than $300 million • 25%
$200 million to $300 million • 25%
AI in Drug Discovery • 25%
Genomics • 25%
Other • 25%
Digital Health • 25%